Gyroscope Therapeutics

Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat ocular diseases that cause vision loss and blindness.

Its lead investigational gene therapy program GT005 is an AAV2-based one-time gene therapy delivering the complement regulatory protein CFI for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GT005 is currently being evaluated in Phase II clinical trials in two different genetically defined patient populations.

Besides GT005, Gyroscope is advancing an expanded pipeline of gene therapies for retinal diseases, leveraging its proprietary OrbitTM subretinal delivery system, which is designed for precise delivery to the back of the eye.